In 1996, topotecan [59] and irinotecan [60], drugs that are DNA topoisomerase I inhibitors (Table 2), were approved for therapies of metastatic ovarian and colorectal cancers, respectively (Table 1). Here, TOP1 is linked to colorectal cancer.